mrkad5 hiv-1 gag/pol/nef
Vaccineexperimental
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2006 (NCT00183261)
Timeline
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mrkad5 hiv-1 gag/pol/nef
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00486408 | Phase 1 | Jul 1, 2007 | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), University of Rochester, University of Washington |
| NCT00413725 | Phase 2 | Jan 1, 2007 | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), University of the Witwatersrand, University of Washington |
| NCT00350623 | Phase 2 | Oct 1, 2006 | Merck |
| NCT00183261 | Phase 2 | Mar 1, 2006 | AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Diego |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 3 | 2 | 2006 |
| HIV Vaccine Trials Network | Academic/Hospital | 2 | 0 | 2 | 2007 |
| University of Washington | Academic/Hospital | 2 | 0 | 2 | 2007 |
| AIDS Clinical Trials Group | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Merck | For profit | 1 | 1 | 1 | 2006 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of the Witwatersrand | Academic/Hospital | 1 | 0 | 1 | 2007 |
8 organizations
Page 1 / 1